


Searching News Database: TRAILBLAZER-ALZ
HSMN NewsFeed - 24 Jun 2021
Lilly's donanemab receives U.S. FDA's Breakthrough Therapy designation for treatment of Alzheimer's disease
Lilly's donanemab receives U.S. FDA's Breakthrough Therapy designation for treatment of Alzheimer's disease
